Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma
- PMID: 37714979
- DOI: 10.1007/s00259-023-06439-2
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma
Abstract
Purpose: Intracytoplasmic melanin pigment is a characteristic of clear cell sarcoma (CCS), which is a particularly deadly type of soft-tissue sarcoma. [18F]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([18F]-PFPN) is a positron emission tomography (PET) probe characterized by high melanin affinity. Therefore, this study aimed to investigate the feasibility of melanin-targeted [18F]-PFPN PET in patients with CCS.
Methods: This prospective single-centre study recruited patients with pathologically confirmed CCS. [18F]-FDG PET/computed tomography and [18F]-PFPN PET/magnetic resonance imaging scans were performed within 1 week of each other. The lesion numbers and [18F]-FDG and [18F]-PFPN PET parameters (maximum standardized uptake value [SUVmax], mean standardized uptake value [SUVmean], metabolic/melanotic tumour volume [MTV/MLTV], and total lesion glycolysis/melanin [TLG/TLM]) were collected.
Results: Three patients with CCS were recruited and received PET imaging. A total of 56 lesions were detected on [18F]-PFPN PET, including primary tumour and distant metastases. Identical lesions were not detected on [18F]-PFPN and [18F]-FDG PET. Twelve lesions (12/39, 30.77%) on [18F]-FDG imaging were missed on [18F]-PFPN, and 20 lesions (20/47, 42.55%) on [18F]-PFPN imaging were missed on [18F]-FDG. In quantitative analysis, the [18F]-FDG SUVmean (4.60 ± 3.24) was higher than the [18F]-PFPN SUVmean (3.0 ± 2.63) in all lesions (P = 0.01). No significant correlations were found between the SUVmax, SUVmean, MLTV/MTV, and TLM/TLG values of [18F]-PFPN and [18F]-FDG (P > 0.05).
Conclusion: Melanin-targeted [18F]-PFPN PET imaging is feasible for the diagnosis of CCS. Different imaging features were displayed on [18F]-PFPN and [18F]-FDG PET imaging, demonstrating the complementary role of the tracers. Combined use of the two imaging modalities would be preferred in patients with CCS.
Clinical trial registration: NCT05963035.
Keywords: Clear cell sarcoma; Melanin; PET/MRI; [18F]-FDG; [18F]-PFPN.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
- 
    - TahiriElousrouti L, Hammas N, Elmernissi FZ, Elfatemi H, Chbani L. Clear-cell sarcoma with an unusual presentation mimicking metastatic melanoma. Cureus. 2022;14(11):e32010. https://doi.org/10.7759/cureus.32010 . - DOI
 
- 
    - Panza E, Ozenberger BB, Straessler KM, Barrott JJ, Li L, Wang Y, et al. The clear cell sarcoma functional genomic landscape. J Clin Invest. 2021;131(15):e146301. https://doi.org/10.1172/jci146301 . - DOI - PubMed - PMC
 
- 
    - WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours, 5th ed. Vol. 3). https://publications.Iarc.fr/588 . Accessed 1 Aug 2023.
 
- 
    - Obiorah IE, Brenholz P, Özdemirli M. Primary clear cell sarcoma of the dermis mimicking malignant melanoma. Balkan Med J. 2018;35(2):203–7. https://doi.org/10.4274/balkanmedj.2017.0796 . - DOI - PubMed - PMC
 
- 
    - Meis-Kindblom JM. Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity. Adv Anat Pathol. 2006;13(6):286–92. https://doi.org/10.1097/01.pap.0000213052.92435.1f . - DOI - PubMed
 
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
- Full Text Sources
- Medical
 
        